Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sanofi is conducting a Phase 3 clinical study titled ‘A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis.’ The study aims to evaluate the efficacy of Frexalimab in delaying disability progression in adults with nonrelapsing secondary progressive multiple sclerosis (nrSPMS), highlighting its significance in potentially offering a new treatment option for this condition.
The intervention being tested is Frexalimab, administered intravenously, designed to assess its safety and effectiveness compared to a placebo in managing nrSPMS. The study also uses MRI contrast-enhancing agents as part of the intervention process.
This study employs a randomized, double-blind, placebo-controlled, parallel group design. It involves quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are all blinded to the treatment allocations. The primary purpose of the study is treatment-focused.
The study began on November 9, 2023, with an estimated completion date of 43 months from the randomization of the first participant. The last update was submitted on August 21, 2025. These dates are crucial for tracking the study’s progress and anticipated results timeline.
The update on this study could influence Sanofi’s stock performance positively, as successful results may enhance investor confidence and market position in the competitive multiple sclerosis treatment landscape. The outcome could also impact competitors focusing on similar therapeutic areas.
The study is currently ongoing, with further details available on the ClinicalTrials portal.